Biweekly 72-hour 9-aminocamptothecin infusion as second-line therapy for ovarian carcinoma: Phase II study of the New York Gynecologic Oncology Group and the Eastern Cooperative Oncology Group Article

Hochster, H, Plimack, ER, Runowicz, CD et al. (2004). Biweekly 72-hour 9-aminocamptothecin infusion as second-line therapy for ovarian carcinoma: Phase II study of the New York Gynecologic Oncology Group and the Eastern Cooperative Oncology Group . JOURNAL OF CLINICAL ONCOLOGY, 22(1), 120-126. 10.1200/JCO.2004.03.016

Open Access

cited authors

  • Hochster, H; Plimack, ER; Runowicz, CD; Speyer, J; Wallach, RC; Sorich, J; Mandeli, J; Wadler, S; Wright, J; Muggia, FM

sustainable development goals

authors

publication date

  • January 1, 2004

webpage

published in

keywords

  • ADULT CANCER-PATIENTS
  • CISPLATIN
  • COLORECTAL-CARCINOMA
  • CYCLOPHOSPHAMIDE
  • GEMCITABINE
  • Life Sciences & Biomedicine
  • Oncology
  • PACLITAXEL
  • PHARMACODYNAMICS
  • RESISTANT OVARIAN
  • Science & Technology
  • TOPOTECAN
  • TRIAL

Digital Object Identifier (DOI)

publisher

  • AMER SOC CLINICAL ONCOLOGY

start page

  • 120

end page

  • 126

volume

  • 22

issue

  • 1